英文_高盛_全球医疗保健生物制药2025年美国临床肿瘤学会（ASCO）会议关注要点_20页_757kb

2025 ASCO Conference Summary for Biopharma Companies

This report analyzes key presentations and data updates from the 2025 American Society of Clinical Oncology (ASCO) conference, focusing on biopharmaceutical advancements. The conference is held from May 30 to June 3, 2025, and serves as a major platform for sharing data across various oncology programs. Goldman Sachs' analysts highlight important developments, including Phase 1/2 updates, key trial results, regulatory implications, and investment risks. The focus is on innovative treatments in cancers such as renal cell carcinoma (RCC), small cell lung cancer (SCLC), breast cancer, and others.

Key Companies and Their Updates

• Amgen (AMGN, Buy): Presenting Phase 3 data on tarlatamab (Imdeltra) in second-line (2L) SCLC, showing improved overall survival (OS) and progression-free survival (PFS) over chemotherapy. Analysts view this as a potential catalyst for label expansion to first-line (1L) settings.

• Regeneron (REGN, Buy): Highlighting adjuvant data for cemiplimab (Libtayo) in high-risk cutaneous squamous cell carcinoma (CSCC), with a 68% reduction in recurrence risk compared to placebo. Additional data on Libtayo in hematologic malignancies and combinations are expected.

• Allogene Therapeutics (ALLO, Early-Stage Biotech): Updating Phase 1/1b data for ALLO-316, targeting advanced RCC with improved safety profiles and longer follow-up showing durable responses in heavily treated patients.

• Biopharmaceutical Innovations: Early-stage companies like BCAX, JAZZ, and IOVA share data on PD-1 inhibitors, CAR-T therapies, and bispecific antibodies. Key areas include combination trials (e.g., BCAX's ficerafusp+pembrolizumab in head and neck cancer) and extended follow-up for melanoma treatments.

• Large Cap Pharmaceuticals: Companies like ABBV, MRK, and PFE have incremental updates focused on ADCs, targeted therapies, and combinations, with SMMT's ivonescimab data in EGFRmutated NSCLC seen as a significant gap filler in the oncology landscape.

• Jazz Pharmaceuticals (JAZZ, Buy): Primary results from the IMforte trial of lurbinectedin plus atezolizumab in 1L extensive-stage SCLC, potentially enabling label expansion beyond its current 2L indication.

Investment Implications

Analysts assign Buy/Neutral/Sell ratings based on clinical success, commercial potential, and risk factors. Downside risks include clinical trial failures, regulatory delays, competition, and reimbursement challenges. Upside potential stems from positive ESR1m subgroup data for ARVN's vepdegestrant or superior efficacy data for regenerative medicines. Valuation sensitivity analyses show key drivers like terminal growth rates and weighted average cost of capital (WACC) affect stock prices.

• Valuation Summary: Ratings and price targets range from $106 (JAZZ, Buy) to $8 (IOVA, Buy), with early-stage companies like ALLO valued under $22. WACC and TGR changes impact forecasts, with higher risks reducing estimates.

Note: This summary captures key events from Goldman Sachs' analysis. Market participants should consider all risks and consult the full report for details.